Top Scoops

Book Reviews | Gordon Campbell | Scoop News | Wellington Scoop | Community Scoop | Search


Moderna follows Pfizer with exciting vaccine news – how to read these dramatic developments

It is very exciting to hear another positive story about vaccine trial results – a good vaccine is the most likely way of ending the pandemic.

Last week, interim results from Pfizer suggested its vaccine reduces cases of COVID-19 with 90% efficacy. Now Moderna has gone one better, with interim results showing nearly 95% efficacy for its vaccine – with hints that it may protect against severe disease. Neither have reported any serious safety concerns and have tested their vaccines in tens of thousands of participants.

With so many COVID-19 vaccines in development, more results are likely to follow in the coming months. Their headline figures may, like these, be very impressive, but it’s necessary to dig deeper to find out exactly what any new results mean.

With that in mind, here are six questions to ask about any new vaccine trial result.

1. Does this mean the vaccine is safe?

Almost certainly yes if it has successfully passed through a phase 3 trial with thousands of participants. Vaccines do not get this far if there are any major doubts about safety.

Historically, pharmaceutical companies have been able to suppress negative results, but it’s now legally required for all trials to post their results so that other scientists can review them. As a consequence the sector is generally far more trusted than it used to be, although we should still be cautious if only interim results are being reported.

Some people are concerned that COVID-19 vaccines have been produced with unprecedented speed; however, the vast majority are based on platform technologies with excellent safety profiles. There are a few newer technologies being used, but the clinical trial and regulatory process is extremely rigorous and will pick up the majority of potential complications fairly early on in development.

A technician working on the Pfizer/BioNTech vaccine at
a BioNTech facility

Both the Pfizer and Moderna COVID-19 vaccines use a novel mRNA-based design. EPA-EFE

Of course, it is still difficult to know yet about long-term side-effects, but these are rare for vaccines, and any risk is normally significantly lower than the risks from getting the disease being vaccinated against.

2. Do the headline figures reflect what the trial was designed to measure?

Trials often measure many things, but there is always a single primary research question or objective that a trial has been designed to answer.

Trials will also have several secondary research questions, but answering these is not considered a mark of success. If you test enough different objectives, a few will always be met due to blind chance. Misrepresenting trial data in this way is a form of research misconduct called p-hacking. You can find out the primary and secondary objectives of any trial by checking a clinical trial registry.

Again, it is important to consider whether these are interim results. Although such results can be promising – as Pfizer and Moderna have shown – they are not guaranteed to be the final result.

3. Did the trial measure the right thing?

Determining what counts as a medicine or drug “working” can be quite complicated for many diseases. But for vaccines, the question to ask is quite simple: did people who had the active vaccine get the disease? Any measure that’s more complicated than this (often referred to as a surrogate outcome) should be treated with caution.

4. Who was the vaccine tested on?

Are the results of a trial transferable to the real world? Here it’s important to understand the difference between a population (in this case everyone who can catch COVID-19) and the sample of that population who took part in the trial.

In many cases, trials use two carefully matched (and so comparable) samples in carefully controlled conditions. One is given the vaccine and the other a placebo (such as saline injection or an already developed vaccine for another disease) to control for the effect of participants thinking they have been vaccinated – which does have an effect.

In phase 1 trials, safety concerns mean that samples are generally made up of young and fit people with few health concerns, who are probably not representative of the overall population. However, as trials progress into later phases and get bigger, researchers try to ensure a more representative sample of the population.

This is why the final-stage (phase 3) trials are so important, as the sample is chosen to represent the population that the vaccine is targeted at. Formal publications of trial results normally provide a table describing who was in the sample, and often efficacy rates for the different groups (broken down by sex, age and so on). Unfortunately, the headline efficacy figure (95% for instance) may not apply evenly across the population.

This is very important for COVID-19, as we know older people are much more vulnerable. We therefore shouldn’t read too much into any results until we can see an age breakdown for efficacy.

5. Will the vaccine be usable?

Before we get too excited, some practical questions must be asked. How much will the vaccine cost? Can it be made in bulk? Is it easy to transport and store? And how many boosters will be needed? These logistic problems (for instance, the requirement to be stored and transported at very low temperatures) can easily prevent a new vaccine getting into the clinic.

A freezer control panel showing -79C.

Pfizer’s vaccine needs to be stored at -80C, which will make rolling it out more difficult. BlurryMe/Shutterstock

6. Can we trust what’s being reported?

It’s an increasingly important skill to identify between reliable and unreliable sources. Social media is often superficial and prone to spreading misinformation. On the other hand, journal articles and clinical trial registries can be hard to interpret for anyone except specialists.

Trusted journalism is the answer. Seek out publications with editorial oversight and a track record of reliable scientific and medical reporting. Reading more than one interpretation can help you get a balanced view.

It’s also important to ask where a journalist found the information they are reporting on. Referencing results published in peer-reviewed journals is a good sign – it shows some rigorous fact checking has occurred. Be careful if an article’s main sources seem to be preprints (papers not yet peer reviewed) or other so-called grey literature, such as press releases or company reports.

Likewise, be careful if the main source seems to be interviews or quotes from people with PhDs or impressive sounding job titles. A quote from a scientist in an interview is not equivalent to a quote from the same scientist in a peer-reviewed academic paper.

© Scoop Media

Top Scoops Headlines


Binoy Kampmark: Biden’s Victory: A Eunuch Presidency Beckons

Whatever was set to happen on November 3, President Donald J. Trump would not lose. Falling in that establishment firebreak against democracy known as the Electoral College would not erase, let alone repudiate him. His now victorious opponent, far ... More>>

Reese Ehrlich: Foreign Correspondent: The Challenge For Joe Biden

If he’s smart, the likely President-elect will stop the unpopular endless wars and use the money to help our domestic economy. By Reese Erlich I’m pissed. I’m pissed at Donald Trump for trying to shut down the vote count early and at Republicans More>>

Boris Johnson At Sea: Coronavirus Confusion In The UK

The tide has been turning against UK Prime Minister Boris Johnson. Oafishly, he has managed to convert that tide into a deluge of dissatisfaction assisted by the gravitational pull of singular incompetence. Much of this is due to such errors of ... More>>

The Conversation: Biodiversity: Where The World Is Making Progress – And Where It’s Not

The future of biodiversity hangs in the balance. World leaders are gathering to review international targets and make new pledges for action to stem wildlife declines. Depending on whether you are a glass half-full or half-empty person, you’re likely ... More>>

The Conversation: The Numbers Suggest The Campaign For Cannabis Reform In NZ Will Outlive The Generations That Voted Against It

Like Brexit in the UK, cannabis reform in New Zealand fell into an age gap — given time, a second referendum would probably succeed. More>>

Gordon Campbell: 22 Short Takes On The US Election

Finally, the long night of Donald Trump’s presidency is over. To date, the courts have been given no cause to conclude that the exhaustively lengthy counts of those mountains of mail ballots was anything other than legal. Stacking the US Supreme ... More>>

Gordon Campbell: On How The US Supreme Court Is Undermining American Democracy

If Joe Biden is elected President next week, here comes the bad news. If Biden tries to defend Obamacare, combat climate change (via say, a variant of the Green New Deal) or tries to improve the access of US women to abortion services , he will run afoul ... More>>

The Coronavirus Republic: Three Million Infections And Rising

The United States is famed for doing things, not to scale, but off it. Size is the be-all and end-all, and the coronavirus is now doing its bit to assure that the country remains unrivalled in the charts of infection . In time, other unfortunates may well ... More>>

  • PublicAddress
  • Pundit
  • Kiwiblog